Showing 2841-2850 of 5685 results for "".
- CVP Partners With Northwest and Central Ohio Ophthalmology Practicehttps://modernod.com/news/cvp-partners-with-northwest-and-central-ohio-ophthalmology-practice/2476202/CEI Vision Partners (CVP) announced that Retina Vitreous Associates (RVA) of Toledo, Ohio is now the newest partner practice to join the CVP platform. RVA is a vitreoretinal surgical practice with nine ophthalmologists who specialize in medical and surgical
- Global Demand for Refractive Surgery Growing After Economic Rebound in Major Marketshttps://modernod.com/news/global-demand-for-refractive-surgery-growing-after-economic-rebound-in-major-markets/2476207/Global demand for refractive surgery is expected to grow at a compound annual rate of 5.2 percent from 2018 to 2023, with annual surgical volume increasing from 4.3 million to 5.5 million procedures, according to the latest Market Scope estimates. Demand for refractive surgery has continued to gr
- Exonate Closes £1.5 Million Fundraising Accelerate Development Eye Drop Treatment for Retinal Neovascular Diseaseshttps://modernod.com/news/exonate-closes-1-5-million-fundraising-accelerate-development-eye-drop-treatment-for-retinal-neovascular-diseases/2476222/Exonate announces the successful closing of its fourth financing round, raising £1.5 million. The funds raised will be used to accelerate the development of Exonate’s lead product, an eye drop for the treatment of retinal neovascular diseases. The company continues to make substantial progress an
- EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019https://modernod.com/news/eyepoint-pharmaceuticals-to-launch-dexycu-and-yutiq-in-first-quarter-of-2019/2476226/During a corporate update, EyePoint Pharmaceuticals executives said they expect to launch both Dexycu (dexamethasone intraocular suspension 9%) and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) in the first quarter of calendar 2019. “EyePoint has made significant progress in
- Ocular Therapeutix Announces Completion of Debt Refinancinghttps://modernod.com/news/ocular-therapeutix-announces-completion-of-debt-refinancing/2476236/Ocular Therapeutix announced that it has closed a refinancing of its existing debt by entering into a new $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility allows for an expansion of the company’s prior $18 million credit facility to $25 mil
- Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordershttps://modernod.com/news/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders/2476249/Japan-based Chugai Pharmaceutical announced that the FDA has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NM
- Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese Markethttps://modernod.com/news/nicox-and-ocumension-therapeutics-sign-exclusive-license-agreement-to-develop-and-commercialize-ncx-470-in-the-chinese-market/2479610/Nicox and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 470, targeting patients with glaucoma or ocular hypertension
- University of Dayton Researcher Named on Second Patent for Device to Provide Better Relief for Glaucoma Patientshttps://modernod.com/news/university-of-dayton-researcher-named-on-second-patent-for-device-to-provide-better-relief-for-glaucoma-patients/2479616/Khalid Lafdi, University of Dayton Wright Brothers Endowed Chair in Nanomaterials, was named on a second patent for a medical drainage device mainly for glaucoma patients that also could be used for drainage in the ears, brain, or chest or to provide access to larger veins or arteries, according
- Ophthalmic Investment Funds Led by Retinal Gene Therapy Developershttps://modernod.com/news/ophthalmic-investment-funds-led-by-retinal-gene-therapy-developers/2476147/Ophthalmology remains one of the most active areas of medical technology investment, attracting monies from venture capitalists, public markets, large ophthalmic companies, and private equity. Market Scope just published its 2017/2018 Ophthalmic Deals Book, analyzing recent ophthalmic fund
- Akorn CEO Steps Down After Loss of $4.3 Billion Fresenius Dealhttps://modernod.com/news/akorn-ceo-steps-down-after-loss-of-4-3-billion-fresenius-deal/2476150/Akorn’s CEO stepped down after the Delaware Supreme Court ruled that a rapid downturn in its business was grounds for Fresenius SE to walk away from a $4.3 billion buyout of the generic drugmaker, according to a Bloomberg News